XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis.

摘要: OBJECTIVES Although platinum-based chemotherapy is widely used for advanced ovarian cancer (OC), genetic polymorphisms can influence the chemotherapeutic response. This study investigated association between XRCC1 Arg194Trp, Arg280His, and Arg399Gln, overall survival (OS) in OC patients who received chemotherapy. METHODS We systematically searched PubMed, Embase, Cochrane library, Chinese National Knowledge Infrastructure, Wanfang, Weipu databases relevant studies from inception to October, 2017. OS was calculated using a random-effects model. Sensitivity, subgroup, publication bias analyses were also performed. RESULTS Five involving 1159 included. When compared with 194ArgArg, 194TrpTrp (hazard ratio [HR] 1.09, 95% confidence interval [CI] 0.71-1.69, P = .69) 194TrpArg (HR 1.00, CI 0.78-1.28, P = .98) carriers not associated OS. Similarly, 280ArgArg carriers, neither 280HisHis 1.39, 0.82 -2.34, P = .22) nor 280HisArg 0.98, 0.73 -1.31, P = .90) affected Furthermore, there no significant differences 399GlnGln 0.46-2.16, P > .99), 399GlnArg 1.05, 0.81-1.37, P = .70), 399ArgArg. Finally, subgroup analysis suggested that significantly decreased when percentage of III or IV cases >80.0% 1.79, 1.22-2.62, P = .003), while increased this <80.0% 0.47, 0.28-0.79, P = .004). CONCLUSIONS indicated Arg399Gln did affect after patients. However, disease status could relationship these